AIM ImmunoTech (AIM)

• Market cap: $2.95M
• 1 day: -3.38%
• 5 days: -3.17%
• 1 month: -28.24%
• 3 months: -51.72%
• 6 months: -72.97%
• Year to date: -41.18%
• 1 year: -94.44%
• 5 years: -99.68%
• 10 years: -99.99%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

Employees: 23